{"id":"W2593067736","doi":"10.1158/1078-0432.ccr-16-2796","title":"A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PARP inhibitor; Ovarian cancer; Germline; Medicine; Cancer research; Germline mutation; Ovarian carcinoma; Internal medicine; Oncology; Cancer; Mutation; Poly ADP ribose polymerase; Biology; Genetics; DNA; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001464121,0.001326898,0.002243269,0.0003558825,0.000504827,0.0008440273,0.0006220864,0.0009321487,0.002964942],"category_scores_gemma":[0.00102908,0.0007684127,0.001049567,0.0004310411,0.0008151772,0.0007181119,0.000316621,0.00295507,0.0007189531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008150145,"about_ca_system_score_gemma":0.00176558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000878704,"about_ca_topic_score_gemma":0.001875989,"domain_scores_codex":[0.9995079,0.0002365407,0.00002710896,0.00009908248,0.0000494862,0.00007989202],"domain_scores_gemma":[0.9992292,0.0001345436,0.0001147866,0.00007118675,0.00004955211,0.000400755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6594992,0.1380446,0.01826742,0.0009747061,0.001637027,0.0005732978,0.0004343642,0.002706826,0.05072147,0.0003000735,0.004889319,0.1219518],"study_design_scores_gemma":[0.5084277,0.4673535,0.01723473,0.00002601878,0.000393567,0.0003422528,0.00005435217,0.001049527,0.002405744,0.0001370486,0.002548712,0.00002675028],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930841,0.001589839,0.0005235683,0.000314882,0.0000910933,0.002390728,0.000553621,0.00005169001,0.00140066],"genre_scores_gemma":[0.9912345,0.00135731,0.001522859,0.0007761379,0.0001964148,0.001994357,0.001527395,0.00002169388,0.001369279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002964942,"threshold_uncertainty_score":0.009918749,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2419675665224092,"score_gpt":0.5440788431986607,"score_spread":0.3021112766762516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}